IDH1 and IDH2 mutations widely occur in gliomas and acute myeloid leukemia [18-21], leading to the production of 2-hydroxyglutarate (2-HG), which inhibits multiple α-KG-dependent dioxygenases, including the TET family of 5-mC hydroxylases (which results in decreased 5-hmC) [22]. The gene discussed is IDH2; the disease is acute myeloid leukemia.